Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909702 | 0.80 | CRHR1 (0.42) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL25259818 | 0.80 | KMT2A (0.39) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL17831133 | 0.78 | GABRA1 (0.39) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL17831097 | 0.78 | GABRA1 (0.39) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL18929949 | 0.78 | RECQL (0.34) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL15281027 | 0.78 | HTT (0.44) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL23902132 | 0.78 | LMNA (0.46) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL23707000 | 0.75 | TRPA1 (0.62) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL29484749 | 0.75 | TRPA1 (0.62) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL17831096 | 0.75 | CYP1A2 (0.41) | ADRA1AMEN1KMT2ACYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626138-B2 | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides | THE SCRIPPS RESEARCH INSTITUTE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT OF HEALTH AND HUMAN SERVICES (DHHS) (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200040027-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | THE SCRIPPS RESEARCH INSTITUTE | 2020-02-06 | — | — | US | disclosed |
| EP-2841413-B1 | PROCESS FOR PREPARING N-(5-CHLORO-2-ISOPROPYLBENZYL)CYCLOPROPANAMINE | BAYER CROPSCIENCE AG (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20160168187-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | Synthorx, Inc. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168187-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | RNGTT, POLM, POLRMT | LMNA 1062/4885TRPA1 4852/4885CHRM1 4683/4885 |
| US-20200040027-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | RNGTT, POLM, POLRMT | LMNA 1062/4885TRPA1 4852/4885CHRM1 4683/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | LMNA 3830/4885TRPA1 4487/4885CHRM1 4883/4885 |
| US-10626138-B2 | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides | RNGTT, POLM, POLRMT | LMNA 878/4885TRPA1 4850/4885CHRM1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.